Skip to main content
. 2018 May 25;11:3141–3147. doi: 10.2147/OTT.S143465

Figure 3.

Figure 3

miR-134 negatively regulates Mnk1/2.

Notes: (A) Predicted binding sequences of miR-134 in the 3′UTR of Mnk1/2. (B) Relative luciferase activity of 293T cells after co-transfection with WT or MUT Mnks 3′UTR or the control reporter plasmid, and miR-134 mimics or negative control. (C) Quantification of Mnk1/2 protein expression in K562/A02 and HL-60/ADM cells. (D) Quantification of Mnk1/2 mRNA expression in 41 newly diagnosed AML patients, 25 relapsed/refractory AML patients, and protein expression in three matched-pair bone marrow samples of AML patients at the diagnosis time prior to treatment and the relapsed/refractory state. (E) Quantification of Mnk1/2 mRNA and protein expression in K562/A02 and HL-60/ADM cells. *p<0.05, **p<0.01.

Abbreviations: 3′UTR, 3′ untranslated region; AML, acute myeloid leukemia; eIF4E, eukaryotic initiation factor 4E; MUT, mutant type; NC, normal control; WT, wild type.